UroGen Pharma Ownership 2024 | Who Owns UroGen Pharma Now?
Institutional Ownership
13.33%
Insider Ownership
9.20%
Retail Ownership
77.47%
Institutional Holders
34.00
UroGen Pharma Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 10.66% | 0.92% | 3,557,347 | 300,000 | 9.21% | 59,692,283 | Jun 30, 2024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 9.89% | 0.10% | 3,300,000 | 2,000,000 | 153.85% | 55,374,000 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 9.24% | 0.68% | 3,083,430 | - | - | 51,739,955 | Jun 30, 2024 |
| GREAT POINT PARTNERS LLC | 8.71% | 9.34% | 2,906,259 | 285,714 | 10.90% | 48,767,026 | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 7.34% | 0.11% | 2,449,277 | 1,337,257 | 120.25% | 41,098,865 | Jun 30, 2024 |
| MENORA MIVTACHIM HOLDINGS LTD. | 6.90% | 0.26% | 2,303,031 | - | - | 38,644,860 | Jun 30, 2024 |
| BLACKROCK INC. | 6.57% | 0.00% | 2,193,950 | 477,137 | 27.79% | 36,814,482 | Jun 30, 2024 |
| COWEN AND COMPANY, LLC | 6.29% | 0.97% | 2,099,482 | 472,893 | 29.07% | 35,229,307 | Jun 30, 2024 |
| MORGAN STANLEY | 5.51% | 0.00% | 1,838,706 | 1,448,157 | 370.80% | 30,853,494 | Jun 30, 2024 |
| CORMORANT ASSET MANAGEMENT, LP | 4.94% | 1.60% | 1,650,000 | 1,650,000 | 100.00% | 27,687,000 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | 3.95% | 0.01% | 1,320,000 | 1,320,000 | 100.00% | 22,149,600 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 3.48% | 0.01% | 1,160,899 | 1,119,019 | 2671.97% | 19,479,885 | Jun 30, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 3.30% | 4.36% | 1,102,000 | 593,413 | 116.68% | 18,491,560 | Jun 30, 2024 |
| JEFFERIES FINANCIAL GROUP INC. | 2.89% | 0.17% | 965,000 | 125,000 | 14.88% | 16,192,700 | Jun 30, 2024 |
| STATE STREET CORP | 2.18% | 0.00% | 726,676 | 189,682 | 35.32% | 12,193,623,000 | Jun 30, 2024 |
| MIGDAL INSURANCE & FINANCIAL HOLDINGS LTD. | 2.06% | 0.19% | 686,472 | - | - | 11,519,000 | Jun 30, 2024 |
| WILDCAT CAPITAL MANAGEMENT, LLC | 1.48% | 2.04% | 495,606 | - | - | 8,316,269 | Jun 30, 2024 |
| DAFNA CAPITAL MANAGEMENT LLC | 1.41% | 1.88% | 469,000 | 469,000 | 100.00% | 7,869,820 | Jun 30, 2024 |
| HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES LTD. | 1.39% | 0.15% | 463,565 | -209,922 | -31.17% | 7,779,000 | Jun 30, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.26% | 0.00% | 421,389 | 97,437 | 30.08% | 7,070,907 | Jun 30, 2024 |
UroGen Pharma's largest institutional shareholder is RTW INVESTMENTS, LP, holding 10.66% of the company's total share outstanding, currently valued at $59.69M. The top 10 institutional shareholders own together 76.04% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| GREAT POINT PARTNERS LLC | 8.71% | 9.34% | 2,906,259 | 285,714 | 10.90% | 48,767,026 | Jun 30, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 3.30% | 4.36% | 1,102,000 | 593,413 | 116.68% | 18,491,560 | Jun 30, 2024 |
| WILDCAT CAPITAL MANAGEMENT, LLC | 1.48% | 2.04% | 495,606 | - | - | 8,316,269 | Jun 30, 2024 |
| DAFNA CAPITAL MANAGEMENT LLC | 1.41% | 1.88% | 469,000 | 469,000 | 100.00% | 7,869,820 | Jun 30, 2024 |
| CORMORANT ASSET MANAGEMENT, LP | 4.94% | 1.60% | 1,650,000 | 1,650,000 | 100.00% | 27,687,000 | Jun 30, 2024 |
| OPALEYE MANAGEMENT INC. | 1.23% | 1.58% | 412,000 | 142,000 | 52.59% | 6,913,360 | Jun 30, 2024 |
| COWEN AND COMPANY, LLC | 6.29% | 0.97% | 2,099,482 | 472,893 | 29.07% | 35,229,307 | Jun 30, 2024 |
| RTW INVESTMENTS, LP | 10.66% | 0.92% | 3,557,347 | 300,000 | 9.21% | 59,692,283 | Jun 30, 2024 |
| RA CAPITAL MANAGEMENT, L.P. | 9.24% | 0.68% | 3,083,430 | - | - | 51,739,955 | Jun 30, 2024 |
| PARKMAN HEALTHCARE PARTNERS LLC | 0.82% | 0.62% | 274,465 | 90,281 | 49.02% | 4,605,523 | Jun 30, 2024 |
| DE LISLE PARTNERS LLP | 0.24% | 0.30% | 81,510 | 4,417 | 5.73% | 1,368,960 | Jun 30, 2024 |
| MENORA MIVTACHIM HOLDINGS LTD. | 6.90% | 0.26% | 2,303,031 | - | - | 38,644,860 | Jun 30, 2024 |
| ATOM INVESTORS LP | 0.43% | 0.24% | 144,780 | 94,990 | 190.78% | 2,429,408 | Jun 30, 2024 |
| ANNANDALE CAPITAL, LLC | 0.23% | 0.22% | 75,552 | -6,000 | -7.36% | 1,268,000 | Jun 30, 2024 |
| MIGDAL INSURANCE & FINANCIAL HOLDINGS LTD. | 2.06% | 0.19% | 686,472 | - | - | 11,519,000 | Jun 30, 2024 |
| JEFFERIES FINANCIAL GROUP INC. | 2.89% | 0.17% | 965,000 | 125,000 | 14.88% | 16,192,700 | Jun 30, 2024 |
| COASTAL BRIDGE ADVISORS, LLC | 0.12% | 0.16% | 38,500 | 1,500 | 4.05% | 646,030 | Jun 30, 2024 |
| HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES LTD. | 1.39% | 0.15% | 463,565 | -209,922 | -31.17% | 7,779,000 | Jun 30, 2024 |
| OAK RIDGE INVESTMENTS LLC | 0.24% | 0.13% | 79,929 | 18,725 | 30.59% | 1,341,209 | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 7.34% | 0.11% | 2,449,277 | 1,337,257 | 120.25% | 41,098,865 | Jun 30, 2024 |
The largest UroGen Pharma shareholder by % of total assets is GREAT POINT PARTNERS LLC. The company owns 2.91M shares of UroGen Pharma (URGN), representing 9.34% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 9.89% | 0.10% | 3,300,000 | 2,000,000 | 153.85% | 55,374,000 | Jun 30, 2024 |
| CORMORANT ASSET MANAGEMENT, LP | 4.94% | 1.60% | 1,650,000 | 1,650,000 | 100.00% | 27,687,000 | Jun 30, 2024 |
| MORGAN STANLEY | 5.51% | 0.00% | 1,838,706 | 1,448,157 | 370.80% | 30,853,494 | Jun 30, 2024 |
| POINT72 ASSET MANAGEMENT, L.P. | 7.34% | 0.11% | 2,449,277 | 1,337,257 | 120.25% | 41,098,865 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | 3.95% | 0.01% | 1,320,000 | 1,320,000 | 100.00% | 22,149,600 | Jun 30, 2024 |
| MILLENNIUM MANAGEMENT LLC | 3.48% | 0.01% | 1,160,899 | 1,119,019 | 2671.97% | 19,479,885 | Jun 30, 2024 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 3.30% | 4.36% | 1,102,000 | 593,413 | 116.68% | 18,491,560 | Jun 30, 2024 |
| BLACKROCK INC. | 6.57% | 0.00% | 2,193,950 | 477,137 | 27.79% | 36,814,482 | Jun 30, 2024 |
| COWEN AND COMPANY, LLC | 6.29% | 0.97% | 2,099,482 | 472,893 | 29.07% | 35,229,307 | Jun 30, 2024 |
| DAFNA CAPITAL MANAGEMENT LLC | 1.41% | 1.88% | 469,000 | 469,000 | 100.00% | 7,869,820 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.91% | 0.05% | 303,740 | 303,740 | 100.00% | 5,096,757 | Jun 30, 2024 |
| RTW INVESTMENTS, LP | 10.66% | 0.92% | 3,557,347 | 300,000 | 9.21% | 59,692,283 | Jun 30, 2024 |
| GREAT POINT PARTNERS LLC | 8.71% | 9.34% | 2,906,259 | 285,714 | 10.90% | 48,767,026 | Jun 30, 2024 |
| STATE STREET CORP | 2.18% | 0.00% | 726,676 | 189,682 | 35.32% | 12,193,623,000 | Jun 30, 2024 |
| GOLDMAN SACHS GROUP INC | 0.79% | 0.00% | 263,606 | 149,744 | 131.51% | 4,423,309 | Jun 30, 2024 |
| BALYASNY ASSET MANAGEMENT L.P. | 0.52% | 0.01% | 173,966 | 148,995 | 596.67% | 2,919,149 | Jun 30, 2024 |
| SCHONFELD STRATEGIC ADVISORS LLC | 0.74% | 0.03% | 248,399 | 144,299 | 138.62% | 4,168,135 | Jun 30, 2024 |
| OPALEYE MANAGEMENT INC. | 1.23% | 1.58% | 412,000 | 142,000 | 52.59% | 6,913,360 | Jun 30, 2024 |
| JEFFERIES FINANCIAL GROUP INC. | 2.89% | 0.17% | 965,000 | 125,000 | 14.88% | 16,192,700 | Jun 30, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | 0.30% | 0.01% | 100,000 | 100,000 | 100.00% | 1,678,000 | Jun 30, 2024 |
As of Jun 30 2024, UroGen Pharma's largest institutional buyer is ADAGE CAPITAL PARTNERS GP, L.L.C.. The company purchased 2.00M stocks of URGN, valued at $55.37M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SUPERSTRING CAPITAL MANAGEMENT LP | - | - | - | -288,267 | -100.00% | - | Jun 30, 2024 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.03% | - | 10,948 | -256,195 | -95.90% | 184,000 | Jun 30, 2024 |
| HAREL INSURANCE INVESTMENTS & FINANCIAL SERVICES LTD. | 1.39% | 0.15% | 463,565 | -209,922 | -31.17% | 7,779,000 | Jun 30, 2024 |
| ALPHACENTRIC ADVISORS LLC | - | - | - | -143,898 | -100.00% | - | Jun 30, 2024 |
| LAURION CAPITAL MANAGEMENT LP | 0.48% | 0.03% | 160,600 | -90,000 | -35.91% | 2,694,868 | Jun 30, 2024 |
| CIBC WORLD MARKETS CORP | - | - | - | -75,000 | -100.00% | - | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | - | - | - | -63,039 | -100.00% | - | Jun 30, 2024 |
| HSBC HOLDINGS PLC | - | - | - | -52,954 | -100.00% | - | Jun 30, 2024 |
| BNP PARIBAS ARBITRAGE, SNC | 0.01% | - | 2,656 | -37,139 | -93.33% | 44,568 | Jun 30, 2024 |
| CERITY PARTNERS LLC | - | - | - | -36,965 | -100.00% | - | Jun 30, 2024 |
| BENDER ROBERT & ASSOCIATES | - | - | - | -34,701 | -100.00% | - | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | - | - | - | -32,800 | -100.00% | - | Jun 30, 2024 |
| UBS GROUP AG | 0.04% | - | 11,887 | -30,980 | -72.27% | 199,464 | Jun 30, 2024 |
| BBR PARTNERS, LLC | - | - | - | -26,000 | -100.00% | - | Jun 30, 2024 |
| AMERIPRISE FINANCIAL INC | 0.14% | 0.00% | 45,075 | -25,877 | -36.47% | 756,358 | Jun 30, 2024 |
| SHIKIAR ASSET MANAGEMENT INC | 0.03% | 0.05% | 10,750 | -22,500 | -67.67% | 180,000 | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | - | - | - | -21,573 | -100.00% | - | Jun 30, 2024 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 0.04% | 0.00% | 13,302 | -19,219 | -59.10% | 223,208 | Jun 30, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | - | - | - | -16,188 | -100.00% | - | Jun 30, 2024 |
| NORTHERN TRUST CORP | 0.65% | 0.00% | 217,362 | -15,138 | -6.51% | 3,647,334,000 | Jun 30, 2024 |
As of Jun 30 2024, UroGen Pharma's biggest institutional seller is SUPERSTRING CAPITAL MANAGEMENT LP. The company sold -0.29M shares of URGN, valued at -.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CORMORANT ASSET MANAGEMENT, LP | 4.94% | 1.60% | 1,650,000 | 1,650,000 | 100.00% | 27,687,000 | Jun 30, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | 3.95% | 0.01% | 1,320,000 | 1,320,000 | 100.00% | 22,149,600 | Jun 30, 2024 |
| DAFNA CAPITAL MANAGEMENT LLC | 1.41% | 1.88% | 469,000 | 469,000 | 100.00% | 7,869,820 | Jun 30, 2024 |
| WOODLINE PARTNERS LP | 0.91% | 0.05% | 303,740 | 303,740 | 100.00% | 5,096,757 | Jun 30, 2024 |
| ALYESKA INVESTMENT GROUP, L.P. | 0.30% | 0.01% | 100,000 | 100,000 | 100.00% | 1,678,000 | Jun 30, 2024 |
| TREXQUANT INVESTMENT LP | 0.24% | 0.02% | 80,709 | 80,709 | 100.00% | 1,354,297 | Jun 30, 2024 |
| CAPTION MANAGEMENT, LLC | 0.22% | 0.02% | 73,700 | 73,700 | 100.00% | 1,236,686 | Jun 30, 2024 |
| CAPTION MANAGEMENT, LLC | 0.20% | 0.02% | 68,000 | 68,000 | 100.00% | 1,141,040 | Jun 30, 2024 |
| MONASHEE INVESTMENT MANAGEMENT LLC | 0.12% | 0.09% | 40,500 | 40,500 | 100.00% | 679,590 | Jun 30, 2024 |
| ALLIANCEBERNSTEIN L.P. | 0.10% | 0.00% | 34,230 | 34,230 | 100.00% | 574,379 | Jun 30, 2024 |
| MAIN STREET FINANCIAL SOLUTIONS, LLC | 0.07% | 0.04% | 24,000 | 24,000 | 100.00% | 402,720 | Jun 30, 2024 |
| OPPENHEIMER & CO INC | 0.06% | 0.01% | 19,323 | 19,323 | 100.00% | 324,240 | Jun 30, 2024 |
| COREBRIDGE FINANCIAL, INC. | 0.06% | 0.00% | 18,481 | 18,481 | 100.00% | 310,111 | Jun 30, 2024 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 0.04% | 0.00% | 14,643 | 14,643 | 100.00% | 245,710 | Jun 30, 2024 |
| PROSHARE ADVISORS LLC | 0.04% | 0.00% | 11,888 | 11,888 | 100.00% | 199,480 | Jun 30, 2024 |
| AWM INVESTMENT COMPANY, INC. | 0.03% | 0.02% | 10,000 | 10,000 | 100.00% | 167,800 | Jun 30, 2024 |
| ACTIVEST WEALTH MANAGEMENT | 0.00% | 0.01% | 1,001 | 1,001 | 100.00% | 16,797 | Jun 30, 2024 |
| SRS CAPITAL ADVISORS, INC. | 0.00% | 0.00% | 56 | 56 | 100.00% | 940 | Jun 30, 2024 |
UroGen Pharma's largest new institutional shareholder by number of shares is CORMORANT ASSET MANAGEMENT, LP, purchased 1.65M shares, valued at $27.69M, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| SUPERSTRING CAPITAL MANAGEMENT LP | - | - | - | -288,267 | -100.00% | - | Jun 30, 2024 |
| ALPHACENTRIC ADVISORS LLC | - | - | - | -143,898 | -100.00% | - | Jun 30, 2024 |
| CIBC WORLD MARKETS CORP | - | - | - | -75,000 | -100.00% | - | Jun 30, 2024 |
| SQUAREPOINT OPS LLC | - | - | - | -63,039 | -100.00% | - | Jun 30, 2024 |
| HSBC HOLDINGS PLC | - | - | - | -52,954 | -100.00% | - | Jun 30, 2024 |
| CERITY PARTNERS LLC | - | - | - | -36,965 | -100.00% | - | Jun 30, 2024 |
| BENDER ROBERT & ASSOCIATES | - | - | - | -34,701 | -100.00% | - | Jun 30, 2024 |
| TD ASSET MANAGEMENT INC | - | - | - | -32,800 | -100.00% | - | Jun 30, 2024 |
| BBR PARTNERS, LLC | - | - | - | -26,000 | -100.00% | - | Jun 30, 2024 |
| JUMP FINANCIAL, LLC | - | - | - | -21,573 | -100.00% | - | Jun 30, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | - | - | - | -16,188 | -100.00% | - | Jun 30, 2024 |
| GSA CAPITAL PARTNERS LLP | - | - | - | -14,937 | -100.00% | - | Jun 30, 2024 |
| AMERICAN INTERNATIONAL GROUP, INC. | - | - | - | -13,664 | -100.00% | - | Jun 30, 2024 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | - | - | - | -10,000 | -100.00% | - | Jun 30, 2024 |
| METROPOLITAN LIFE INSURANCE CO/NY | - | - | - | -1,586 | -100.00% | - | Jun 30, 2024 |
| FIRST MANHATTAN CO. LLC. | - | - | - | -1,500 | -100.00% | - | Jun 30, 2024 |
| PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO | - | - | - | -1,400 | -100.00% | - | Jun 30, 2024 |
| EVERSOURCE WEALTH ADVISORS, LLC | - | - | - | -57 | -100.00% | - | Jun 30, 2024 |
| SYSTM WEALTH SOLUTIONS LLC | - | - | - | -48 | -100.00% | - | Jun 30, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | - | -4 | -100.00% | - | Jun 30, 2024 |
UroGen Pharma's largest sold out institutional shareholder by shares sold is SUPERSTRING CAPITAL MANAGEMENT LP, sold -0.29M shares, valued at -, as of undefined.
UroGen Pharma Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| Trust for Advised Portfolios | 0.04% | 719,146 | - | - | Dec 31, 2023 |
| ETF Managers Trust | 0.00% | 28,862 | 7,302 | 33.87% | Dec 31, 2023 |
| ALPS ETF Trust | 0.00% | 36,565 | - | - | Feb 29, 2024 |
| MML SERIES INVESTMENT FUND | 0.00% | 20,726 | - | - | Dec 31, 2023 |
| CLEARWATER INVESTMENT TRUST | 0.00% | 12,390 | - | - | Mar 28, 2024 |
| VANGUARD WHITEHALL FUNDS | 0.00% | 64,390 | - | - | Jan 31, 2024 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.00% | 79 | - | - | Mar 31, 2024 |
| NEW COVENANT FUNDS | 0.00% | 1,543 | - | - | Dec 31, 2023 |
| Global X Funds | 0.00% | 10,577 | - | - | Jan 31, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 14,441 | - | - | Feb 29, 2024 |
| JOHN HANCOCK INVESTMENT TRUST | 0.00% | 17,879 | - | - | Mar 31, 2024 |
| NORTHERN FUNDS | 0.00% | 30,066 | 96 | 0.32% | Mar 28, 2024 |
| Dunham Funds | 0.00% | 11,983 | - | - | Jan 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 424 | - | - | Mar 31, 2024 |
| HC CAPITAL TRUST | 0.00% | 3,560 | - | - | Mar 31, 2024 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 124,249 | 46,155 | 59.10% | Feb 29, 2024 |
| VANGUARD WELLINGTON FUND | 0.00% | 24,528 | 9,772 | 66.22% | Feb 29, 2024 |
| MUTUAL FUND SERIES TRUST | 0.00% | 143,898 | -11,102 | -7.16% | Mar 31, 2024 |
| VICTORY PORTFOLIOS | 0.00% | 853 | - | - | Mar 31, 2024 |
| TIAA-CREF FUNDS | 0.00% | 71,342 | 10,304 | 16.88% | Jan 31, 2024 |
| ProFunds | 0.00% | 215 | -14 | -6.11% | Mar 31, 2024 |
| USAA MUTUAL FUNDS TRUST | 0.00% | 2,895 | - | - | Jan 31, 2024 |
| PGIM ETF TRUST | 0.00% | 790 | - | - | Feb 29, 2024 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 1,060 | 413 | 63.83% | Feb 29, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 9,811 | - | - | Mar 31, 2024 |
| JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 16,460 | 5,805 | 54.48% | Mar 31, 2024 |
| ETF Series Solutions | 0.00% | 128 | - | - | Jan 31, 2024 |
| Brinker Capital Destinations Trust | 0.00% | 354 | - | - | Feb 29, 2024 |
| Invesco Exchange-Traded Fund Trust II | 0.00% | 823 | 289 | 54.12% | Feb 29, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 1,634 | - | - | Dec 31, 2023 |
| Bridge Builder Trust | 0.00% | 6,341 | - | - | Mar 31, 2024 |
| John Hancock Funds II | 0.00% | 5,800 | 3,328 | 134.63% | Feb 29, 2024 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 0.00% | 7,696 | - | - | Feb 29, 2024 |
| SEI INSTITUTIONAL MANAGED TRUST | 0.00% | 852 | -46,111 | -98.19% | Dec 31, 2023 |
UroGen Pharma's largest mutual fund holder by % of total assets is "Trust for Advised Portfolios", owning 719.15K shares, compromising 0.04% of its total assets.
UroGen Pharma Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 30 Jun, 24 | 34 | -70.94% |
| 31 Mar, 24 | 117 | 8.33% |
| 31 Dec, 23 | 108 | 1.89% |
| 30 Sep, 23 | 106 | 19.10% |
| 30 Jun, 23 | 89 | 30.88% |
| 31 Mar, 23 | 68 | 3.03% |
| 31 Dec, 22 | 66 | 8.20% |
| 30 Sep, 22 | 61 | -3.17% |
| 30 Jun, 22 | 63 | -23.17% |
| 31 Mar, 22 | 82 | 10.81% |
| 31 Dec, 21 | 74 | -20.43% |
| 30 Sep, 21 | 93 | 13.41% |
| 30 Jun, 21 | 82 | -8.89% |
| 31 Mar, 21 | 90 | 8.43% |
| 31 Dec, 20 | 83 | - |
| 30 Sep, 20 | 83 | -9.78% |
| 30 Jun, 20 | 92 | 10.84% |
| 31 Mar, 20 | 83 | -8.79% |
| 31 Dec, 19 | 91 | 4.60% |
| 30 Sep, 19 | 87 | - |
| 30 Jun, 19 | 87 | 14.47% |
| 31 Mar, 19 | 76 | 18.75% |
| 31 Dec, 18 | 64 | -11.11% |
| 30 Sep, 18 | 72 | 18.03% |
| 30 Jun, 18 | 61 | 38.64% |
| 31 Mar, 18 | 44 | 4.76% |
| 31 Dec, 17 | 42 | 31.25% |
| 30 Sep, 17 | 32 | 52.38% |
| 30 Jun, 17 | 21 | - |
As of 30 Jun 24, 34 institutions are holding UroGen Pharma's shares, representing a decrease of -70.94% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 30 Jun, 24 | 4,449,664 | -83.62% |
| 31 Mar, 24 | 27,162,135 | 26.89% |
| 31 Dec, 23 | 21,406,800 | 20.71% |
| 30 Sep, 23 | 17,734,025 | 34.25% |
| 30 Jun, 23 | 13,209,673 | 5.37% |
| 31 Mar, 23 | 12,536,107 | -3.73% |
| 31 Dec, 22 | 13,022,062 | -2.24% |
| 30 Sep, 22 | 13,320,203 | -0.93% |
| 30 Jun, 22 | 13,445,872 | -5.47% |
| 31 Mar, 22 | 14,224,333 | -3.40% |
| 31 Dec, 21 | 14,725,593 | 4.54% |
| 30 Sep, 21 | 14,086,103 | 0.82% |
| 30 Jun, 21 | 13,971,582 | -2.30% |
| 31 Mar, 21 | 14,299,773 | -1.72% |
| 31 Dec, 20 | 14,549,927 | -3.12% |
| 30 Sep, 20 | 15,019,015 | 2.36% |
| 30 Jun, 20 | 14,673,091 | 4.87% |
| 31 Mar, 20 | 13,991,859 | -1.43% |
| 31 Dec, 19 | 14,195,433 | -2.63% |
| 30 Sep, 19 | 14,578,235 | -1.04% |
| 30 Jun, 19 | 14,731,827 | 9.24% |
| 31 Mar, 19 | 13,485,187 | 40.68% |
| 31 Dec, 18 | 9,585,717 | -3.40% |
| 30 Sep, 18 | 9,923,014 | 1.48% |
| 30 Jun, 18 | 9,777,836 | 5.79% |
| 31 Mar, 18 | 9,242,564 | 33.14% |
| 31 Dec, 17 | 6,942,190 | 50.75% |
| 30 Sep, 17 | 4,605,159 | -2.38% |
| 30 Jun, 17 | 4,717,389 | - |
UroGen Pharma (URGN) has 4.45M shares outstanding as of 30 Jun 24, down -83.62% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 30 Jun, 24 | 13.33% | 0.24% |
| 31 Mar, 24 | 75.13% | 1.71% |
| 31 Dec, 23 | 66.28% | 1.16% |
| 30 Sep, 23 | 75.59% | 2.35% |
| 30 Jun, 23 | 56.74% | 1.96% |
| 31 Mar, 23 | 53.85% | 1.69% |
| 31 Dec, 22 | 56.40% | 1.65% |
| 30 Sep, 22 | 58.43% | 1.67% |
| 30 Jun, 22 | 59.22% | 1.50% |
| 31 Mar, 22 | 62.85% | 1.46% |
| 31 Dec, 21 | 65.64% | 1.66% |
| 30 Sep, 21 | 62.94% | 1.61% |
| 30 Jun, 21 | 62.57% | 1.51% |
| 31 Mar, 21 | 64.29% | 1.44% |
| 31 Dec, 20 | 66.80% | 1.44% |
| 30 Sep, 20 | 68.09% | 1.50% |
| 30 Jun, 20 | 67.45% | 1.54% |
| 31 Mar, 20 | 66.13% | 1.38% |
| 31 Dec, 19 | 69.15% | 1.42% |
| 30 Sep, 19 | 69.70% | 1.39% |
| 30 Jun, 19 | 70.71% | 1.45% |
| 31 Mar, 19 | 69.73% | 1.99% |
| 31 Dec, 18 | 59.13% | 1.56% |
| 30 Sep, 18 | 61.66% | 1.61% |
| 30 Jun, 18 | 61.95% | 1.69% |
| 31 Mar, 18 | 60.54% | 1.19% |
| 31 Dec, 17 | 71.45% | 5.74% |
| 30 Sep, 17 | 35.29% | 1.34% |
| 30 Jun, 17 | 51.25% | - |
As of 30 Jun 24, UroGen Pharma is held by 13.33% institutional shareholders, representing a 0.24% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 21 | -58.00% |
| 31 Mar, 24 | 50 | -24.24% |
| 31 Dec, 23 | 66 | 6.45% |
| 30 Sep, 23 | 62 | 34.78% |
| 30 Jun, 23 | 46 | 58.62% |
| 31 Mar, 23 | 29 | 20.83% |
| 31 Dec, 22 | 24 | 60.00% |
| 30 Sep, 22 | 15 | -25.00% |
| 30 Jun, 22 | 20 | -44.44% |
| 31 Mar, 22 | 36 | 33.33% |
| 31 Dec, 21 | 27 | -30.77% |
| 30 Sep, 21 | 39 | 30.00% |
| 30 Jun, 21 | 30 | -11.76% |
| 31 Mar, 21 | 34 | -2.86% |
| 31 Dec, 20 | 35 | 20.69% |
| 30 Sep, 20 | 29 | -44.23% |
| 30 Jun, 20 | 52 | 48.57% |
| 31 Mar, 20 | 35 | -30.00% |
| 31 Dec, 19 | 50 | -10.71% |
| 30 Sep, 19 | 56 | 7.69% |
| 30 Jun, 19 | 52 | -13.33% |
| 31 Mar, 19 | 60 | 71.43% |
| 31 Dec, 18 | 35 | -14.63% |
| 30 Sep, 18 | 41 | -8.89% |
| 30 Jun, 18 | 45 | 45.16% |
| 31 Mar, 18 | 31 | 10.71% |
| 31 Dec, 17 | 28 | 47.37% |
| 30 Sep, 17 | 19 | -9.52% |
| 30 Jun, 17 | 21 | - |
21 institutional shareholders have increased their position in URGN stock as of 30 Jun 24 compared to 50 in the previous quarter (a -58.00% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 30 Jun, 24 | 6 | -83.78% |
| 31 Mar, 24 | 37 | 85.00% |
| 31 Dec, 23 | 20 | -9.09% |
| 30 Sep, 23 | 22 | 10.00% |
| 30 Jun, 23 | 20 | 33.33% |
| 31 Mar, 23 | 15 | -21.05% |
| 31 Dec, 22 | 19 | -17.39% |
| 30 Sep, 22 | 23 | -4.17% |
| 30 Jun, 22 | 24 | 9.09% |
| 31 Mar, 22 | 22 | - |
| 31 Dec, 21 | 22 | -8.33% |
| 30 Sep, 21 | 24 | -14.29% |
| 30 Jun, 21 | 28 | -20.00% |
| 31 Mar, 21 | 35 | 34.62% |
| 31 Dec, 20 | 26 | -16.13% |
| 30 Sep, 20 | 31 | 82.35% |
| 30 Jun, 20 | 17 | -43.33% |
| 31 Mar, 20 | 30 | 25.00% |
| 31 Dec, 19 | 24 | 71.43% |
| 30 Sep, 19 | 14 | -30.00% |
| 30 Jun, 19 | 20 | 122.22% |
| 31 Mar, 19 | 9 | -52.63% |
| 31 Dec, 18 | 19 | - |
| 30 Sep, 18 | 19 | 58.33% |
| 30 Jun, 18 | 12 | 71.43% |
| 31 Mar, 18 | 7 | -12.50% |
| 31 Dec, 17 | 8 | 33.33% |
| 30 Sep, 17 | 6 | - |
| 30 Jun, 17 | - | - |
6 institutional shareholders have reduced their position in URGN stock as of 30 Jun 24 compared to 37 in the previous quarter (a -83.78% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Jun, 24 | 34 | -70.94% | 4,449,664 | -83.62% | 13.33% | 0.24% | 21 | -58.00% | 6 | -83.78% |
| 31 Mar, 24 | 117 | 8.33% | 27,162,135 | 26.89% | 75.13% | 1.71% | 50 | -24.24% | 37 | 85.00% |
| 31 Dec, 23 | 108 | 1.89% | 21,406,800 | 20.71% | 66.28% | 1.16% | 66 | 6.45% | 20 | -9.09% |
| 30 Sep, 23 | 106 | 19.10% | 17,734,025 | 34.25% | 75.59% | 2.35% | 62 | 34.78% | 22 | 10.00% |
| 30 Jun, 23 | 89 | 30.88% | 13,209,673 | 5.37% | 56.74% | 1.96% | 46 | 58.62% | 20 | 33.33% |
| 31 Mar, 23 | 68 | 3.03% | 12,536,107 | -3.73% | 53.85% | 1.69% | 29 | 20.83% | 15 | -21.05% |
| 31 Dec, 22 | 66 | 8.20% | 13,022,062 | -2.24% | 56.40% | 1.65% | 24 | 60.00% | 19 | -17.39% |
| 30 Sep, 22 | 61 | -3.17% | 13,320,203 | -0.93% | 58.43% | 1.67% | 15 | -25.00% | 23 | -4.17% |
| 30 Jun, 22 | 63 | -23.17% | 13,445,872 | -5.47% | 59.22% | 1.50% | 20 | -44.44% | 24 | 9.09% |
| 31 Mar, 22 | 82 | 10.81% | 14,224,333 | -3.40% | 62.85% | 1.46% | 36 | 33.33% | 22 | - |
| 31 Dec, 21 | 74 | -20.43% | 14,725,593 | 4.54% | 65.64% | 1.66% | 27 | -30.77% | 22 | -8.33% |
| 30 Sep, 21 | 93 | 13.41% | 14,086,103 | 0.82% | 62.94% | 1.61% | 39 | 30.00% | 24 | -14.29% |
| 30 Jun, 21 | 82 | -8.89% | 13,971,582 | -2.30% | 62.57% | 1.51% | 30 | -11.76% | 28 | -20.00% |
| 31 Mar, 21 | 90 | 8.43% | 14,299,773 | -1.72% | 64.29% | 1.44% | 34 | -2.86% | 35 | 34.62% |
| 31 Dec, 20 | 83 | - | 14,549,927 | -3.12% | 66.80% | 1.44% | 35 | 20.69% | 26 | -16.13% |
| 30 Sep, 20 | 83 | -9.78% | 15,019,015 | 2.36% | 68.09% | 1.50% | 29 | -44.23% | 31 | 82.35% |
| 30 Jun, 20 | 92 | 10.84% | 14,673,091 | 4.87% | 67.45% | 1.54% | 52 | 48.57% | 17 | -43.33% |
| 31 Mar, 20 | 83 | -8.79% | 13,991,859 | -1.43% | 66.13% | 1.38% | 35 | -30.00% | 30 | 25.00% |
| 31 Dec, 19 | 91 | 4.60% | 14,195,433 | -2.63% | 69.15% | 1.42% | 50 | -10.71% | 24 | 71.43% |
| 30 Sep, 19 | 87 | - | 14,578,235 | -1.04% | 69.70% | 1.39% | 56 | 7.69% | 14 | -30.00% |
| 30 Jun, 19 | 87 | 14.47% | 14,731,827 | 9.24% | 70.71% | 1.45% | 52 | -13.33% | 20 | 122.22% |
| 31 Mar, 19 | 76 | 18.75% | 13,485,187 | 40.68% | 69.73% | 1.99% | 60 | 71.43% | 9 | -52.63% |
| 31 Dec, 18 | 64 | -11.11% | 9,585,717 | -3.40% | 59.13% | 1.56% | 35 | -14.63% | 19 | - |
| 30 Sep, 18 | 72 | 18.03% | 9,923,014 | 1.48% | 61.66% | 1.61% | 41 | -8.89% | 19 | 58.33% |
| 30 Jun, 18 | 61 | 38.64% | 9,777,836 | 5.79% | 61.95% | 1.69% | 45 | 45.16% | 12 | 71.43% |
| 31 Mar, 18 | 44 | 4.76% | 9,242,564 | 33.14% | 60.54% | 1.19% | 31 | 10.71% | 7 | -12.50% |
| 31 Dec, 17 | 42 | 31.25% | 6,942,190 | 50.75% | 71.45% | 5.74% | 28 | 47.37% | 8 | 33.33% |
| 30 Sep, 17 | 32 | 52.38% | 4,605,159 | -2.38% | 35.29% | 1.34% | 19 | -9.52% | 6 | - |
| 30 Jun, 17 | 21 | - | 4,717,389 | - | 51.25% | - | 21 | - | - | - |
UroGen Pharma Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of UroGen Pharma's stock was made by Schoenberg Mark on Jun 11 2024, selling 5,153 shares at $13.08 per share (valued at $67.40K).
UroGen Pharma Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | 7 | - | - |
| Q2 2024 | 1 | 2 | 50.00% |
| Q1 2024 | 12 | 20 | 60.00% |
| Q3 2023 | 14 | 2 | 700.00% |
| Q2 2023 | 1 | - | - |
| Q1 2023 | 17 | 13 | 130.77% |
| Q4 2022 | 4 | 4 | 100.00% |
| Q3 2022 | 5 | 6 | 83.33% |
| Q2 2022 | 15 | 5 | 300.00% |
| Q1 2022 | 18 | 20 | 90.00% |
| Q4 2021 | 5 | 8 | 62.50% |
| Q3 2021 | 1 | 5 | 20.00% |
| Q2 2021 | 15 | 6 | 250.00% |
| Q1 2021 | 21 | 11 | 190.91% |
| Q4 2020 | 12 | 14 | 85.71% |
| Q3 2020 | 9 | 11 | 81.82% |
| Q2 2020 | 16 | 14 | 114.29% |
| Q1 2020 | 17 | 15 | 113.33% |
| Q4 2019 | 7 | 6 | 116.67% |
| Q3 2019 | 4 | 8 | 50.00% |
7 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by UroGen Pharma's insiders, as of Q3 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q3 2024 | - | - | - |
| Q2 2024 | - | 1 | - |
| Q1 2024 | - | 13 | - |
| Q3 2023 | - | 1 | - |
| Q2 2023 | - | - | - |
| Q1 2023 | - | 5 | - |
| Q4 2022 | - | 1 | - |
| Q3 2022 | - | 2 | - |
| Q2 2022 | - | 1 | - |
| Q1 2022 | - | 9 | - |
| Q4 2021 | 1 | 4 | 25.00% |
| Q3 2021 | - | 2 | - |
| Q2 2021 | 2 | 2 | 100.00% |
| Q1 2021 | - | 2 | - |
| Q4 2020 | 1 | 5 | 20.00% |
| Q3 2020 | - | 4 | - |
| Q2 2020 | - | 5 | - |
| Q1 2020 | - | 5 | - |
| Q4 2019 | 4 | 2 | 200.00% |
| Q3 2019 | - | 4 | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of UroGen Pharma's stocks.
UroGen Pharma Peer Ownership
| Ticker | Company |
|---|---|
| VIGL | Vigil Neuroscience, Inc. |
| SRRK | Scholar Rock Holding Corporation |
| PRTC | PureTech Health plc |
| IKNA | Ikena Oncology, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| INBX | Inhibrx Biosciences, Inc. |
| GBIO | Generation Bio Co. |
| VACC | Barinthus Biotherapeutics plc |
| TYRA | Tyra Biosciences, Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| KRON | Kronos Bio, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| PEPG | PepGen Inc. |
| XLO | Xilio Therapeutics, Inc. |
| TARA | Protara Therapeutics, Inc. |
| OVID | Ovid Therapeutics Inc. |
| CELC | Celcuity Inc. |
| MACK | Merrimack Pharmaceuticals, Inc. |
| CMPX | Compass Therapeutics, Inc. |
| ELVN | Enliven Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |
URGN Ownership FAQ
Who Owns UroGen Pharma?
UroGen Pharma is owned by institutional shareholders (13.33%), insiders (9.20%), and public (77.47%). The largest institutional shareholder of UroGen Pharma is RTW INVESTMENTS, LP (10.66% of total shares) and the top mutual fund owner is Trust for Advised Portfolios (0.04% of total shares).
Who are the major institutional shareholders of UroGen Pharma?
UroGen Pharma's major institutional shareholders are RTW INVESTMENTS, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., RA CAPITAL MANAGEMENT, L.P., GREAT POINT PARTNERS LLC, and POINT72 ASSET MANAGEMENT, L.P.. The top five shareholders own together 45.83% of the company's share outstanding.
How many UroGen Pharma shareholders are there?
As of Jun 2024, there are 34 institutional shareholders of UroGen Pharma.
What percentage of UroGen Pharma is owned by RTW INVESTMENTS, LP?
RTW INVESTMENTS, LP owns 3.56M shares of UroGen Pharma, representing 10.66% of the company's total shares outstanding, valued at $59.69M (as of Jun 2024).
What percentage of UroGen Pharma is owned by ADAGE CAPITAL PARTNERS GP, L.L.C?
As of Jun 2024, ADAGE CAPITAL PARTNERS GP, L.L.C holds 3.3M shares of UroGen Pharma (URGN), compromising 9.89% of the company, valued at $55.37M.
What percentage of UroGen Pharma is owned by RA CAPITAL MANAGEMENT, L.P?
RA CAPITAL MANAGEMENT, L.P is the third largest holder of UroGen Pharma. The company owns 3.08M of the company's shares outstanding (worth $51.74M).